Voyager is seeking a highly motivated neuroscientist and leader with substantial experience and demonstrated success with early stage drug discovery for Alzheimer\u2019s Disease and tau protein-related neurodegeneration to provide biology leadership for advancing our AAV gene therapy tau program. This is an ideal position for an individual who is energetic and thrives in a team-oriented, fast-paced, and cross-disciplinary small biotech company environment. This role is located in Cambridge, MA.
Responsibilities Biology leadership for the tau program.
Development of preclinical program plans in research, communication of changes and progress, and sharing of expertise with others.
Management of a small team of scientists and research associates.
Attendance of relevant scientific conferences to network with academia and industry, and to stay current in relevant research. \u00a0Requirements: Ph.D. in Neuroscience with 8-12 years industry experience.
Minimum of 5 years experience in a supervisory role in industry
Extensive experience with tau and neurodegeneration
Significant experience with drug discovery and development for neurological disorders, including neurodegenerative diseases
In-depth familiarity with target validation and lead identification and optimization using molecular, cellular, and in vivo methodologies
Outstanding problem-solving skills
Ability to be highly productive in a fluid and fast-paced work environment
Strong publication record and experience in presenting research
Ability to independently analyze and present data to scientific team Strongly Preferred Experience with antibody drug discovery and development for neurodegenerative diseases
Experience on cross-functional therapeutic program team
Experience within a start-up or small biotech environment
Website : http://www.voyagertherapeutics.com/
Voyager Therapeutics is developing life-changing gene therapies for fatal and debilitating diseases of the central nervous system. Our founders include scientific and clinical leaders in the fields of adeno-associated virus (AAV) gene therapy, expressed RNA interference and neuroscience. Our management team has deep expertise and a track record of building exceptional life science companies. We have developed a product engine that may transform treatment for a wide range of diseases, and we have multiple clinical and preclinical product programs. Our pipeline includes VY-AADC01 for Parkinson’s disease, which is in an ongoing Phase 1b study with our collaborators at the University of California, San Francisco, as well as preclinical programs VY-SOD101 for a monogenic form of amyotrophic lateral sclerosis (ALS), VY-FXN01 for Friedreich’s ataxia and VY-HTT01 for Huntington's disease.